<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906605</url>
  </required_header>
  <id_info>
    <org_study_id>CR108224</org_study_id>
    <secondary_id>64041809PCR2002</secondary_id>
    <secondary_id>2016-001917-26</secondary_id>
    <nct_id>NCT02906605</nct_id>
  </id_info>
  <brief_title>A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer</brief_title>
  <official_title>An Open-label, Randomized, Phase 2 Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the anti-tumor activity of JNJ-809 combined with
      apalutamide is improved compared with apalutamide alone for subjects with metastatic
      castration-resistant prostate cancer (mCRPC).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study start delayed due to pending collection and analysis of additional phase 1 data.
  </why_stopped>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Prostate-specific Antigen (PSA) Progression</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Time to PSA progression will be measured using Prostate Cancer Working Group 3 (PCWG3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA Doubling Time (PSADT)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>The PSADT will be determined using the method as recommended by PCWG3 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Progression-free Survival</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Radiographic progression-free survival, is defined as the time from the date of randomization to the date of radiographic progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Unequivocal Clinical Progression</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Time to unequivocal clinical progression defined as the time from the date of randomization to the date of unequivocal clinical progression as evaluated by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Overall survival defined as time from the date of randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Comparison of the AE profiles of the two treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Culture and Shedding Profile of JNJ-809 From Cultured Samples of Feces, Urine, and Saliva</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Blood culture samples will be collected after the mandatory prophylactic antibiotic therapy. Bacterial shedding will be evaluated from cultured samples of feces by stool or rectal swab, urine, and sputum.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostatic Neoplasms, Castration-Resistant</condition>
  <arm_group>
    <arm_group_label>JNJ-809 plus Apalutamide (Group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JNJ-809 given as an infusion and Apalutamide 240 milligram (mg) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apalutamide (Group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apalutamide 240 mg orally daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-809</intervention_name>
    <description>JNJ-809 (1*10^9) colony forming units (CFU) given as an infusion.</description>
    <arm_group_label>JNJ-809 plus Apalutamide (Group A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Apalutamide 240 mg orally daily.</description>
    <arm_group_label>JNJ-809 plus Apalutamide (Group A)</arm_group_label>
    <arm_group_label>Apalutamide (Group B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adenocarcinoma of the prostate

          -  Metastatic disease as documented by technetium-99m (99mTc) bone scan or metastatic
             lesions by computed tomography (CT) or magnetic resonance imaging (MRI) scans

          -  Surgically or medically castrated, with testosterone levels of less than (&lt;)50
             nanogram per deciliter (ng/dL)

          -  Castration-resistant prostate cancer documented by time to prostate-specific antigen
             (PSA) increase during continuous treatment with androgen deprivation therapy (ADT) OR
             radiographic progression of soft tissues OR radiographic progression of bone according
             to PCWG3

        Exclusion Criteria:

          -  Predominately small cell or neuroendocrine carcinoma of the prostate

          -  Known brain metastases (even if treated) or untreated epidural spread

          -  Prior chemotherapy for prostate cancer, except if administered in the
             adjuvant/neoadjuvant setting, or up to 6 cycles of docetaxel for metastatic
             hormone-sensitive prostate cancer

          -  Treatment with medications known to lower the seizure threshold or any investigational
             agent that were not discontinued or substituted greater than or equal to (&gt;=)28 days
             prior to randomization
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

